References
- 1. Xiao, X., M.C. Pickering, and R.J. Smith. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. in Seminars in thrombosis and hemostasis. 2014. Thieme Medical Publishers.
- 2. Hou, J., G.S. Markowitz, A.S. Bomback, G.B. Appel, L.C. Herlitz, et al., Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney international, 2014. 85 p. 450-456.
- 3. Bomback, A.S. and G.B. Appel, Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nature Reviews Nephrology, 2012. 8 p. 634.23026947
- 4. Fakhouri, F., V. Frémeaux-Bacchi, L.-H. Noël, H.T. Cook, and M.C. Pickering, C3 glomerulopathy: a new classification. Nature Reviews Nephrology, 2010. 6 p. 494.2060662810.1038/nrneph.2010.85
- 5. Pickering, M.C., V.D. D’agati, C.M. Nester, R.J. Smith, M. Haas, et al., C3 glomerulopathy: consensus report. Kidney international, 2013. 84 p. 1079–1089.10.1038/ki.2013.37724172683
- 6. Sethi, S., F.C. Fervenza, Y. Zhang, L. Zand, J.A. Vrana, et al., C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney international, 2012. 82 p. 465–473.2267388710.1038/ki.2012.212
- 7. Medjeral-Thomas, N.R., M.M. O’Shaughnessy, J.A. O’Regan, C. Traynor, M. Flanagan, et al., C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clinical Journal of the American Society of Nephrology, 2014. 9 p. 46–53.10.2215/CJN.04700513
- 8. Lu, D.-F., M. Moon, L.D. Lanning, A.M. McCarthy, and R.J. Smith, Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatric nephrology, 2012. 27 p. 773–781.
- 9. Barbour, T.D., M.C. Pickering, and H.T. Cook, Recent insights into C3 glomerulopathy. Nephrology Dialysis Transplantation, 2013. 28 p. 1685–1693.10.1093/ndt/gfs430
- 10. Levey, A.S., J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, et al., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine, 1999. 130 p. 461–470.
- 11. National, K.F., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2002. 39 p. S1.
- 12. Cattran, D.C., J. Feehally, H.T. Cook, Z.H. Liu, F.C. Fervenza, et al., Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney International Supplements, 2012. 2 p. 139–274.
- 13. Cameron, J.S., D.R. Turner, J. Heaton, D.G. Williams, C.S. Ogg, et al., Idiopathic mesangiocapillary glomerulonephritis: Comparison of types I and II in children and adults and long-term prognosis. The American journal of medicine, 1983. 74 p. 175–192.10.1016/0002-9343(83)90606-X
- 14. Nasr, S.H., A.M. Valeri, G.B. Appel, J. Sherwinter, M.B. Stokes, et al., Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clinical Journal of the American Society of Nephrology, 2009. 4 p. 22–32.10.2215/CJN.03480708
- 15. Vikse, B.E., L. Bostad, K. Aasarød, D.E. Lysebo, and B.M. Iversen, Prognostic factors in mesangioproliferative glomerulonephritis. Nephrology Dialysis Transplantation, 2002. 17 p. 1603–1613.10.1093/ndt/17.9.1603
- 16. Zhang, Y., C.M. Nester, B. Martin, M.-O. Skjoedt, N.C. Meyer, et al., Defining the complement biomarker profile of C3 glomerulopathy. Clinical Journal of the American Society of Nephrology, 2014. 9 p. 1876–1882.10.2215/CJN.01820214
- 17. Caliskan, Y., E.S. Torun, T.O. Tiryaki, A. Oruc, Y. Ozluk, et al., Immunosuppressive treatment in C3 glomerulopathy: is it really effective? American journal of nephrology, 2017. 46 p. 96–107.10.1159/000479012
- 18. Rabasco, C., T. Cavero, E. Román, J. Rojas-Rivera, T. Olea, et al., Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney international, 2015. 88 p. 1153–1160.
- 19. Zuber, J., F. Fakhouri, L.T. Roumenina, C. Loirat, and V. Frémeaux-Bacchi, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 2012. 8 p. 643.
- 20. Zhao, W., Y. Ding, J. Lu, T. Zhang, D. Chen, et al., Genetic analysis of the complement path-way in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2018.
- 21. Zipfel, P.F., C. Skerka, Q. Chen, T. Wiech, T. Goodship, et al., The role of complement in C3 glomerulopathy. Molecular immunology, 2015. 67 p. 21–30.
- 22. Rodriguez-Osorio, L. and A. Ortiz, Timing of eculizumab therapy for C3 glomerulonephritis. Clinical kidney journal, 2015. 8 p. 449–452.
- 23. Pickering, M., J. Warren, K. Rose, F. Carlucci, Y. Wang, et al., Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proceedings of the National Academy of Sciences, 2006. 103 p. 9649–9654.
- 24. Vivarelli, M., A. Pasini, and F. Emma, Eculizumab for the treatment of dense-deposit disease. New England Journal of Medicine, 2012. 366 p. 1163–1165.
- 25. McCaughan, J., D. O’rourke, and A. Courtney, Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. American Journal of Transplantation, 2012. 12 p. 1046–1051.10.1111/j.1600-6143.2011.03923.x
- 26. Welte, T., F. Arnold, J. Kappes, M. Seidl, K. Häffner, et al., Treating C3 glomerulopathy with eculizumab. BMC nephrology, 2018. 19 p. 7.